Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

Blood Adv. 2023 Dec 12;7(23):7235-7238. doi: 10.1182/bloodadvances.2023011295.

Authors

Andrew J Portuguese^{1

2}, Min Fang^{1

2}, Sherilyn A Tuazon^{1

3}, Margot Pont^{1

4}, Xiaoyu Qu^{1

2}, Carolyn Shasha¹, Melissa Comstock¹, Justina Lyons¹, Gabriel Cole^{1

4}, Evan W Newell^{1

2}, Emily Glynn², Lorinda A Soma^{1

5}, Damian J Green^{1

2}

Affiliations

¹ Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.
² University of Washington, Department of Medicine, Seattle, WA.
³ Bristol Myers Squibb, Seattle, WA.
⁴ CellPoint Bio, a Galapagos company, Oegstgeest, The Netherlands.
⁵ City of Hope Medical Center, Department of Pathology, Duarte, CA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

ADP-ribosyl Cyclase 1 / genetics
Antibodies, Monoclonal
Antigenic Drift and Shift
Gene Deletion
Humans
Multiple Myeloma* / pathology

Substances

Antibodies, Monoclonal
ADP-ribosyl Cyclase 1

Grants and funding